Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia

ROCKVILLE, MD — May 13, 2015 — Therabron Therapeutics, Inc. (Therabron), a specialty biotechnology company focused on the advancement of respiratory therapeutics with disease-modifying potential, today announced that the European […]

By |May 13th, 2015|Recent News|

Therabron Therapeutics Names Thomas F. Miller President and Chief Operating Officer

ROCKVILLE, MD, May 7, 2015 — Therabron Therapeutics, Inc. (Therabron), a specialty biotechnology company focused on the advancement of respiratory therapeutics with disease-modifying potential, announced that it has named Thomas […]

By |May 7th, 2015|Recent News|

Therabron Therapeutics, Inc. Secures Up to $11M in Series B Financing

Rockville, MD. – December 17, 2014 – www.therabron.com a privately held clinical-stage biotechnology company, today announced that it has secured an investment of up to $11.1M in multiple tranches […]

By |December 17th, 2014|Recent News|

Clarassance is now Therabron Therapeutics

Rockville, MD. – December 12, 2014 – Clarassance, a privately held clinical-stage biotechnology company based in Maryland, today announced its new name: Therabron Therapeutics, Inc, which will serve it well […]

By |December 12th, 2014|Recent News|

Therabron Therapeutics Initiates Phase 2 Clinical Study for Orphan Drug CG100

PHASE 2 STUDY SUPPORTED BY A $1.6M GRANT FROM THE FDA OFFICE OF ORPHAN PRODUCT DEVELOPMENT

Therabron Therapeutics, a privately held clinical stage biopharmaceutical company, today announced that it has initiated the Phase […]

By |March 17th, 2014|Recent News|

Therabron Therapeutics Receives Grant from US Army

Therabron Therapeutics received a $986k, 2 year grant from the USAMRAA to evaluate its lead product, the rhCC10 protein, as a therapeutic to treat inhalation lung injury due to smoke […]

By |September 24th, 2012|Recent News|

Therabron Therapeutics Sponsors Event for Neonatal Drug Development Fund

The Neonatal Drug Development Fund (NDDF) is a philanthropic research fund, created at the Floating Hospital for Children at Tufts Medical Center with the support of Therabron Therapeutics, Inc. The […]

By |December 14th, 2010|Recent News|

Therabron Therapeutics Receives Federal QTDP Tax Grant

A $1Billion tax credit/grant program, part of the 2010 federal stimulus package, was intended to bolster the biotechnology industry during the current recession.  The program was administered by the IRS […]

By |October 29th, 2010|Recent News|

Therabron Therapeutics Presents Poster and Talk at GRC Workshop

Therabron Therapeutics’s Chief Scientist, Dr. Aprile Pilon, was invited to present a poster and to give a short presentation at a workshop entitled, “Mechanisms of Lung Injury and Immunomodulator Interventions […]

By |March 21st, 2010|Recent News|

Therabron Therapeutics Signs CRADA with NIH to Research Second Secretoglobin Drug Candidate

Therabron Therapeutics and the NIH’s National Cancer Institute have entered into a Cooperative Research and Development Agreement (CRADA) in order to perform research on another member of the secretoglobin family called […]

By |August 7th, 2009|Recent News|